Quantum BioPharma Ltd Stock Price, News & Analysis

Quantum BioPharma (NASDAQ: QNTM) has announced the first successful scan of a multiple sclerosis (MS) patient in a joint study with Massachusetts General Hospital (MGH). The study utilizes a novel PET tracer [18F]3F4AP to monitor myelin integrity and demyelination in MS patients. The scanning was performed using a new GE Signa PET-MR scanner, which allows simultaneous PET and MRI imaging, improving spatial and temporal coregistration while reducing patient scan time. This imaging technique could potentially serve as a biomarker to measure the effectiveness of drugs like Quantum's investigational MS drug Lucid-21-302. The PET tracer, developed by Dr. Pedro Brugarolas at MGH, has shown promising results in previous animal and human studies, demonstrating high sensitivity to demyelinated lesions and favorable pharmacokinetics.

Quantum BioPharma (NASDAQ: QNTM) has announced plans to issue special dividend Contingent Value Rights (CVRs) to holders of Class B Subordinate Voting Shares on a 1:1 basis. The CVRs will entitle holders to receive between 10-50% of net proceeds from the company's ongoing litigation against major banks, including CIBC World Markets and RBC Dominion Securities. The litigation seeks damages exceeding $700 million related to alleged stock price manipulation. These CVRs will be non-transferable, non-interest bearing, without voting rights, and redeemable only if the company receives proceeds from the litigation settlement. The exact payout percentage and record date are yet to be determined, and the CVRs will not be listed on any exchange.

Quantum BioPharma (NASDAQ: QNTM) has expanded its cryptocurrency investment portfolio to USD $5,000,000 through additional purchases of Bitcoin (BTC) and other digital currencies. The Board of Directors-approved investment demonstrates the company's strategic approach to using cryptocurrencies as both an investment vehicle and a hedge against the dollar. The company has established infrastructure to accept cryptocurrency-based financing and execute various transactions, with all digital assets being held by a compliant custodian. Quantum BioPharma maintains flexibility to adjust its cryptocurrency holdings based on market conditions while ensuring full compliance with financial and audit regulations.

Quantum BioPharma (NASDAQ: QNTM) has issued a clarification regarding misinformation circulating about its relationship with Unbuzzd Wellness Inc. The company confirms it has not changed its name, contrary to incorrect listings on some trading platforms. Quantum BioPharma is currently the largest shareholder of Unbuzzd Wellness Inc., with significant financial interests including a 7% royalty on revenue (reducing to 3% after $250M), 200M post-split common shares, and an anti-dilution warrant for maintaining 25% ownership. Unbuzzd Wellness Inc. has secured a $1.3M loan from Quantum with 10% annual interest. Additionally, Unbuzzd has hired MNP LLP for PCAOB audits in preparation for a potential IPO. The company also announced a minor debt settlement of $20,930 with Class B Shares.

Quantum BioPharma (NASDAQ: QNTM) has reached a global settlement agreement with its former CEO Dr. Raza Bokhari, resulting in a $2.35 million USD non-dilutive cash payment to the company. The settlement resolves all outstanding disputes stemming from a proxy contest that began in January 2021, including multiple legal proceedings in Canada and the United States. The agreement, signed by current Co-Chairmen & CEO Zeeshan Saeed and Anthony Durkacz, settles various court cases, arbitration awards, and legal claims between the parties. Notable judgments included multiple awards with interest rates ranging from 4% to 6% per annum. All parties acknowledged they acted in shareholders' best interests, with no admission of wrongdoing from any side.

Unbuzzd Wellness Inc. (formerly Celly Nutrition Corp.), a licensee of Quantum BioPharma (NASDAQ: QNTM), has taken significant steps toward a potential IPO by hiring MNP LLP as its new PCAOB-registered audit firm effective May 20, 2025. This follows the company's February 2025 announcement of retaining a New York investment bank for capital raising and IPO exploration.

The company, known for its unbuzzd™ beverage that accelerates alcohol metabolism and reduces hangover symptoms, is led by CEO John Duffy, former Coca-Cola VP, and Board Co-Chair Gerry David, former CEO of Celsius Holdings. The company also completed a name change to Unbuzzd Wellness Inc. effective May 23, 2025, with new CUSIP (90429T100) and ISIN (CA90429T1003) numbers.

Quantum BioPharma (NASDAQ: QNTM) has received Human Ethics Review Committee approval in Australia for a Phase 2 clinical trial of FSD202, targeting nociplastic pain in patients with Idiopathic Mast Cell Activation Syndrome (MCAS). The trial will be a randomized, double-blind, placebo-controlled study involving 60 patients who will receive either FSD202 or placebo twice daily for 56 days.

The study's primary endpoint is measuring the decrease in average daily pain intensity from baseline to Day 28. FSD202, containing ultra-micronized palmitoylethanolamide (PEA), aims to address inflammatory diseases, particularly MCAS, which causes multisystem symptoms and chronic widespread musculoskeletal pain. Currently, MCAS has no known cure, and patients suffer from repeated anaphylactic symptoms and chronic pain.

[ "Phase 2 trial approval received from ethics committee, advancing clinical development pipeline", "Trial targets MCAS, which currently has no cure, representing a significant market opportunity", "FSD202 has potential applications beyond MCAS in other inflammatory diseases", "Well-designed trial with clear endpoints and controlled study parameters" ]

Quantum BioPharma (NASDAQ: QNTM) has announced a partnership with BitGo Trust Company to manage and store its cryptocurrency holdings, including Bitcoin, Solana, XRP, and DOGE coins. BitGo will provide institutional-grade custody services featuring multi-signature wallets and 100% cold storage technology to protect against theft, loss, and unauthorized access.

The partnership aims to enhance security and compliance for Quantum's crypto assets, with BitGo offering an insurance policy as an additional security layer. CEO Zeeshan Saeed emphasized that this collaboration aligns with the company's security and compliance priorities as a public company.

Quantum BioPharma (NASDAQ: QNTM) has signed an agreement with a global pharmaceutical contract research organization to prepare an Investigational New Drug (IND) application for Lucid-21-302 (Lucid-MS), targeting submission to the FDA in Q4 2025. The successful IND application will enable the company to proceed with Phase 2 trials for multiple sclerosis treatment.

Lucid-21-302 is a first-in-class, non-immunomodulatory, neuroprotective compound with a unique mechanism of action. This patented New Chemical Entity has demonstrated ability in preclinical models to prevent demyelination, a known cause of MS and other neurodegenerative diseases affecting the myelin sheath around nerve fibers.